Summary
The Sorafenib HCC Assessment Randomized Protocol [SHARP] trial demonstrated that treatment with sorafenib prolonged overall survival by 44% and prolonged time to progression by 73% for patients with advanced hepatocellular carcinoma.
- Gastrointestinal Cancers Clinical Trials
- © 2007 MD Conference Express
Tools
Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase 3 Randomized, Placebo-Controlled Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.